Trial Outcomes & Findings for Comparison of Intravascular Uptake and Pain Perception During Epidural Injection Using 22 Gauge vs 25 Gauge Needle (NCT NCT04350307)

NCT ID: NCT04350307

Last Updated: 2020-07-20

Results Overview

The intravascular uptake percentage reported in the study is the percent of 'needles' that showed intravascular uptake. Hence higher 'intravascular uptake percentage' means worse outcome. The mean percentages were averaged across participants were compared between treatment arms. Presence or absence of intravascular uptake during live fluoroscopy and/or blood aspiration per needle. Once needle reached its target (epidural space), contrast was injected to confirm the presence or absence of intravascular uptake via live fluoroscopy or aspiration was attempted using a syringe to confirm the presence or absence of intravascular uptake. If contrast pattern suggested needle was in a vessel or blood was aspirated using a syringe, outcome measure was marked 'PRESENT'. If contrast pattern suggested needle was not in a vessel and no blood was aspirated using a syringe, outcome measure was marked 'ABSENT'. In other words, primary outcome measure was binary in nature.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

162 participants

Primary outcome timeframe

During the procedure

Results posted on

2020-07-20

Participant Flow

Participant milestones

Participant milestones
Measure
22-Gauge Arm
Patient undergoing epidural injection in this arm will get 22-gauge Quincke needle 22-gauge needle: 22-gauge Quincke needle used for epidural injection
25-Gauge Arm
Patient undergoing epidural injection in this arm will get 25-gauge Quincke needle 25-gauge needle: 25-gauge Quincke needle used for epidural injection
Overall Study
STARTED
84
78
Overall Study
COMPLETED
84
78
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
22-Gauge Arm
n=84 Participants
Patient undergoing epidural injection in this arm will get 22-gauge Quincke needle 22-gauge needle: 22-gauge Quincke needle used for epidural injection
25-Gauge Arm
n=78 Participants
Patient undergoing epidural injection in this arm will get 25-gauge Quincke needle 25-gauge needle: 25-gauge Quincke needle used for epidural injection
Total
n=162 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=84 Participants
0 Participants
n=78 Participants
0 Participants
n=162 Participants
Age, Categorical
Between 18 and 65 years
24 Participants
n=84 Participants
20 Participants
n=78 Participants
44 Participants
n=162 Participants
Age, Categorical
>=65 years
60 Participants
n=84 Participants
58 Participants
n=78 Participants
118 Participants
n=162 Participants
Age, Continuous
60 years
STANDARD_DEVIATION 2 • n=84 Participants
57 years
STANDARD_DEVIATION 3 • n=78 Participants
58 years
STANDARD_DEVIATION 2 • n=162 Participants
Sex: Female, Male
Female
46 Participants
n=84 Participants
37 Participants
n=78 Participants
83 Participants
n=162 Participants
Sex: Female, Male
Male
38 Participants
n=84 Participants
41 Participants
n=78 Participants
79 Participants
n=162 Participants
Race and Ethnicity Not Collected
0 Participants
Race and Ethnicity were not collected from any participant.
Region of Enrollment
United States
84 participants
n=84 Participants
78 participants
n=78 Participants
162 participants
n=162 Participants

PRIMARY outcome

Timeframe: During the procedure

The intravascular uptake percentage reported in the study is the percent of 'needles' that showed intravascular uptake. Hence higher 'intravascular uptake percentage' means worse outcome. The mean percentages were averaged across participants were compared between treatment arms. Presence or absence of intravascular uptake during live fluoroscopy and/or blood aspiration per needle. Once needle reached its target (epidural space), contrast was injected to confirm the presence or absence of intravascular uptake via live fluoroscopy or aspiration was attempted using a syringe to confirm the presence or absence of intravascular uptake. If contrast pattern suggested needle was in a vessel or blood was aspirated using a syringe, outcome measure was marked 'PRESENT'. If contrast pattern suggested needle was not in a vessel and no blood was aspirated using a syringe, outcome measure was marked 'ABSENT'. In other words, primary outcome measure was binary in nature.

Outcome measures

Outcome measures
Measure
22-Gauge Arm
n=84 Participants
Patient undergoing epidural injection in this arm will get 22-gauge Quincke needle 22-gauge needle: 22-gauge Quincke needle used for epidural injection
25-Gauge Arm
n=78 Participants
Patient undergoing epidural injection in this arm will get 25-gauge Quincke needle 25-gauge needle: 25-gauge Quincke needle used for epidural injection
Intravascular Uptake
5.9 percentage of total number of needle
Interval 1.9 to 9.8
7.1 percentage of total number of needle
Interval 2.4 to 11.8

SECONDARY outcome

Timeframe: During the procedure

Population: Average NRS during the initial needle entry

Patient reported pain during the procedure (on initial needle entry) on the numerical rating scale (NRS 1-10). Higher numbers implies higher severity of pain. Lower numbers implies lower severity of pain

Outcome measures

Outcome measures
Measure
22-Gauge Arm
n=84 Participants
Patient undergoing epidural injection in this arm will get 22-gauge Quincke needle 22-gauge needle: 22-gauge Quincke needle used for epidural injection
25-Gauge Arm
n=78 Participants
Patient undergoing epidural injection in this arm will get 25-gauge Quincke needle 25-gauge needle: 25-gauge Quincke needle used for epidural injection
Patient Reported Pain
3.46 score on a scale
Interval 2.94 to 3.98
3.13 score on a scale
Interval 2.57 to 3.69

Adverse Events

22-Gauge Arm

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

25-Gauge Arm

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Robin Raju

Yale University

Phone: 203-688-8800

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place